Axsome Therapeutics (AXSM) Gross Profit (2022 - 2025)
Historic Gross Profit for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to $159.1 million.
- Axsome Therapeutics' Gross Profit rose 6514.92% to $159.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $515.6 million, marking a year-over-year increase of 6724.51%. This contributed to the annual value of $352.4 million for FY2024, which is 4410.62% up from last year.
- According to the latest figures from Q3 2025, Axsome Therapeutics' Gross Profit is $159.1 million, which was up 6514.92% from $136.6 million recorded in Q2 2025.
- Axsome Therapeutics' Gross Profit's 5-year high stood at $159.1 million during Q3 2025, with a 5-year trough of $7.8 million in Q2 2022.
- Over the past 4 years, Axsome Therapeutics' median Gross Profit value was $73.9 million (recorded in 2024), while the average stood at $74.9 million.
- In the last 5 years, Axsome Therapeutics' Gross Profit skyrocketed by 43720.81% in 2023 and then tumbled by 2105.03% in 2024.
- Quarter analysis of 4 years shows Axsome Therapeutics' Gross Profit stood at $22.1 million in 2022, then soared by 190.54% to $64.2 million in 2023, then surged by 68.74% to $108.3 million in 2024, then skyrocketed by 46.95% to $159.1 million in 2025.
- Its Gross Profit was $159.1 million in Q3 2025, compared to $136.6 million in Q2 2025 and $111.7 million in Q1 2025.